![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
Pennington Biomedical Research Center, Louisiana State University, Baton Rouge, LA 70808
2To whom correspondence should be addressed. E-mail: hardmawe{at}pbrc.edu.
Supplementing the diet of tumor-bearing mice or rats with oils containing (n-3) (omega-3) or with purified (n-3) fatty acids has slowed the growth of various types of cancers, including lung, colon, mammary, and prostate. The efficacy of cancer chemotherapy drugs such as doxorubicin, epirubicin, CPT-11, 5-fluorouracil, and tamoxifen, and of radiation therapy has been improved when the diet included (n-3) fatty acids. Some potential mechanisms for the activity of (n-3) fatty acids against cancer include modulation of eicosanoid production and inflammation, angiogenesis, proliferation, susceptibility for apoptosis, and estrogen signaling. In humans, (n-3) fatty acids have also been used to suppress cancer-associated cachexia and to improve the quality of life. In one study, the response to chemotherapy therapy was better in breast cancer patients with higher levels of (n-3) fatty acids in adipose tissue [indicating past consumption of (n-3) fatty acids] than in patients with lower levels of (n-3) fatty acids. Thus, in combination with standard treatments, supplementing the diet with (n-3) fatty acids may be a nontoxic means to improve cancer treatment outcomes and may slow or prevent recurrence of cancer. Used alone, an (n-3) supplement may be a useful alternative therapy for patients who are not candidates for standard toxic cancer therapies.
KEY WORDS: • (n-3) fatty acids • cancer • nutrition • alternative cancer therapy
This article has been cited by other articles:
|
|
 |
|
  E. R. Tuller, C. T. Beavers, J. R. Lou, M. A. Ihnat, D. M. Benbrook, and W.-Q. Ding Docosahexaenoic Acid Inhibits Superoxide Dismutase 1 Gene Transcription in Human Cancer Cells: The Involvement of Peroxisome Proliferator-Activated Receptor {alpha} and Hypoxia-Inducible Factor-2{alpha} Signaling Mol. Pharmacol., September 1, 2009; 76(3): 588 - 595. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Whelan Dietary Stearidonic Acid Is a Long Chain (n-3) Polyunsaturated Fatty Acid with Potential Health Benefits J. Nutr., January 1, 2009; 139(1): 5 - 10. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Geelen, J. M. Schouten, C. Kamphuis, B. E. Stam, J. Burema, J. M. S. Renkema, E.-J. Bakker, P. van't Veer, and E. Kampman Fish Consumption, n-3 Fatty Acids, and Colorectal Cancer: A Meta-Analysis of Prospective Cohort Studies Am. J. Epidemiol., November 15, 2007; 166(10): 1116 - 1125. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Doyle, L. H. Kushi, T. Byers, K. S. Courneya, W. Demark-Wahnefried, B. Grant, A. McTiernan, C. L. Rock, C. Thompson, T. Gansler, et al. Nutrition and Physical Activity During and After Cancer Treatment: An American Cancer Society Guide for Informed Choices CA Cancer J Clin, November 1, 2006; 56(6): 323 - 353. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Lee, K. M. Gura, S. Kim, D. A. Arsenault, B. R. Bistrian, and M. Puder Current Clinical Applications of {Omega}-6 and {Omega}-3 Fatty Acids Nutr Clin Pract, August 1, 2006; 21(4): 323 - 341. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. F. McCarty and K. I. Block Multifocal Angiostatic Therapy: An Update Integr Cancer Ther, December 1, 2005; 4(4): 301 - 314. [Abstract] [PDF]
|
|
|
|
|
|
K. L. Fritsche Are Omega-3 Fatty Acids Effective in Enhancing Tumoricidal Cell Activity? J. Nutr., December 1, 2005; 135(12): 2916S - 2917S. [Full Text] [PDF]
|
|
